aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. aerovate's initial focus is on advancing av-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or pah.
Company profile
Ticker
AVTE
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Aerovate Securities Corporation ...
IRS number
831377888
AVTE stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
13 May 24
8-K
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
13 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Regulation FD Disclosure
27 Mar 24
10-K
2023 FY
Annual report
25 Mar 24
8-K
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
25 Mar 24
S-8
Registration of securities for employees
8 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
Latest ownership filings
4
Hunter Gillies
17 May 24
4
TIMOTHY P NOYES
17 May 24
144
Notice of proposed sale of securities
17 May 24
144
Notice of proposed sale of securities
16 May 24
4
Marinus Verwijs
3 May 24
4
TIMOTHY P NOYES
3 May 24
144
Notice of proposed sale of securities
2 May 24
144
Notice of proposed sale of securities
1 May 24
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
30 Apr 24
4
Benjamin T Dake
19 Apr 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 9.12 mm | 9.12 mm | 9.12 mm | 9.12 mm | 9.12 mm | 9.12 mm |
Cash burn (monthly) | 4.79 mm | 1.45 mm | 8.21 mm | 7.37 mm | 7.89 mm | 5.75 mm |
Cash used (since last report) | 8.89 mm | 2.70 mm | 15.22 mm | 13.66 mm | 14.64 mm | 10.67 mm |
Cash remaining | 236.53 k | 6.42 mm | -6.10 mm | -4.54 mm | -5.52 mm | -1.55 mm |
Runway (months of cash) | 0.0 | 4.4 | -0.7 | -0.6 | -0.7 | -0.3 |
Institutional ownership, Q4 2023
30.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 4 |
Opened positions | 1 |
Closed positions | 58 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 206.35 mm |
Total shares | 8.90 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Sofinnova Venture Partners X | 3.76 mm | $72.81 mm |
Atlas Venture Associates XII | 3.10 mm | $61.89 mm |
Atlas Venture Fund XII | 2.04 mm | $62.24 mm |
Fortitude Family Office | 416.00 | $9.41 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 May 24 | Hunter Gillies | Common Stock | Sell | Dispose S | No | Yes | 21.86 | 86 | 1.88 k | 5,602 |
17 May 24 | Hunter Gillies | Common Stock | Sell | Dispose S | No | Yes | 21.0658 | 3,914 | 82.45 k | 5,688 |
17 May 24 | Hunter Gillies | Common Stock | Option exercise | Acquire M | No | Yes | 2.14 | 4,000 | 8.56 k | 9,602 |
17 May 24 | Hunter Gillies | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 2.14 | 4,000 | 8.56 k | 11,324 |
16 May 24 | Timothy P Noyes | Common Stock | Sell | Dispose S | No | Yes | 21.922 | 1,293 | 28.35 k | 0 |
16 May 24 | Timothy P Noyes | Common Stock | Sell | Dispose S | No | Yes | 21.5241 | 8,707 | 187.41 k | 1,293 |
16 May 24 | Timothy P Noyes | Common Stock | Option exercise | Acquire M | No | Yes | 2.14 | 10,000 | 21.40 k | 10,000 |
16 May 24 | Timothy P Noyes | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 2.14 | 10,000 | 21.40 k | 343,381 |
2 May 24 | Marinus Verwijs | Common Stock | Sell | Dispose S | No | No | 21.015 | 1,981 | 41.63 k | 0 |
1 May 24 | Timothy P Noyes | Common Stock | Sell | Dispose S | No | Yes | 19.91 | 1,357 | 27.02 k | 0 |
News
Wedbush Reiterates Outperform on Aerovate Therapeutics, Maintains $41 Price Target
22 May 24
Aerovate Therapeutics Presents Baseline Data From Phase 2b Portion Of IMPAHCT Trial At ATS 2024 International Conference
21 May 24
Wedbush Reiterates Outperform on Aerovate Therapeutics, Maintains $41 Price Target
14 May 24
Aerovate Therapeutics Q1 2024 GAAP EPS $(0.83) Misses $(0.74) Estimate
13 May 24
Ermenegildo Zegna Reports FY23 Results, Joins Altice USA, Herbalife And Other Big Stocks Moving Lower On Friday
5 Apr 24
Press releases
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference
21 May 24
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
13 May 24
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
27 Mar 24
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
25 Mar 24